Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects

MLA

Justus G. Garweg, et al. “Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects.” Ophthalmology and Therapy, vol. 12, no. 2, Jan. 2023, pp. 639–55. EBSCOhost, https://doi.org/10.1007/s40123-023-00647-7.

APA

Justus G. Garweg, Claudine A. Blum, René-Pierre Copt, Chiara M. Eandi, Katja Hatz, Christian F. Prünte, Eleonora Seelig, & Gábor M. Somfai. (2023). Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects. Ophthalmology and Therapy, 12(2), 639–655. https://doi.org/10.1007/s40123-023-00647-7

Chicago

Justus G. Garweg, Claudine A. Blum, René-Pierre Copt, Chiara M. Eandi, Katja Hatz, Christian F. Prünte, Eleonora Seelig, and Gábor M. Somfai. 2023. “Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects.” Ophthalmology and Therapy 12 (2): 639–55. doi:10.1007/s40123-023-00647-7.